≥99% HPLCPre-filled pen

Ipamorelin / CJC-1295 (Blend)

Name: Ipamorelin / CJC-1295 (Blend)
Brand: Dripfy
Availability: InStock

What it is?

This is a research-grade blend of two growth-hormone-axis peptides: ipamorelin, a selective ghrelin-mimetic GH secretagogue, and CJC-1295 (no DAC), a GHRH analog. It combines their signalling pathways and is investigational; it is not an approved medicine.

Dripfy Advantage

Two complementary pathways: pairs a GHS-R1a secretagogue (ipamorelin) with a GHRH-receptor analog (CJC-1295) on the rationale that the pathways may act complementarily (hedged).
Ipamorelin component: understood to act as a selective ghrelin mimetic with a comparatively targeted secretagogue profile.
CJC-1295 component: understood to engage pituitary GHRH receptors and prompt pulsatile growth-hormone release.
Compounded uncertainty: combining two compounds compounds the uncertainty; evidence for the combination specifically is very limited.
Physician-directed: Any regimen is determined solely by the supervising physician.

Research & Investigational Focus

GH / IGF-1 axis: investigated for growth-hormone / IGF-1 axis support via two complementary pathways.
Lean-mass & recovery: studied within lean-mass, recovery and body-composition research.
Body composition & sleep: explored for body-composition and sleep-quality signalling.

Composition & Formulation

Format: Pre-filled pen
Purity: ≥99% by HPLC/MS
Supervision: Physician-directed use only

€622

Order by email

Submit an enquiry and we arrange the consultation, physician review and shipping. Physician recommendation required; not medical advice.

Purity: ≥99%
Form: Pre-filled pen
Download Certificate of Analysis: Certificate of Analysis available on request

Important medical notice

A physician recommendation is mandatory before use.
The information on this website is educational only and is not medical advice, diagnosis, or treatment.
Always consult a qualified physician before starting any peptide.
Dosing is individualised and determined by your treating physician.

Peptide Practice Guide

Each card summarises what the peptide is studied for and its evidence strength. It is not a recommendation. Dosing and suitability are decided by your physician.

Ipamorelin / CJC-1295 (Blend)

GH-secretagogue + GHRH-analog blend (investigational) · Pre-filled pen

D· Preliminary evidence

This blend combines two growth-hormone-axis peptides. Ipamorelin is understood to act as a selective ghrelin-mimetic secretagogue at the GHS-R1a receptor, while CJC-1295 (no DAC) is a GHRH analog understood to stimulate pituitary GHRH receptors. Combining a secretagogue with a GHRH analog is investigated on the rationale that the two pathways may act complementarily on pulsatile GH release; however, evidence for the combination specifically is very limited, and combining compounds compounds the uncertainty. Any pathway effect should be regarded as provisional.

Studied use areas

Investigated for growth-hormone / IGF-1 axis support via two complementary pathways
Studied within lean-mass, recovery and body-composition research
Explored for body-composition and sleep-quality signalling
Researched as a combined GH-axis approach rather than for any specific disease

Safety & status

Investigational blend; combining two compounds compounds the uncertainty and the safety profile is not established
Use only under qualified physician supervision
Not for use in pregnancy or breastfeeding, or with active or suspected malignancy (GH/IGF-1 axis considerations)

⚕ Clinical note: This ipamorelin / CJC-1295 blend is an investigational, research-grade combination and not an approved medicine; blending compounds increases uncertainty and it is intended for physician-directed use only. This content is educational, not medical advice.

Evidence: Grade D — investigational; limited human data, mainly preclinical · References: Raun et al., European Journal of Endocrinology 1998; Teichman et al., Journal of Clinical Endocrinology & Metabolism 2006; Sigalos & Pastuszak, Sexual Medicine Reviews 2018